All In Biotech

Drug Trial Radar · NCT05676034

AMX0035 in Adult Patients With Wolfram Syndrome

A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram Syndrome

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Actual

Start

Mar 3, 2023

Primary completion

Jul 23, 2024

Study completion May 31, 2028

Sponsor

Lead sponsor
Amylyx Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jan 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.

Conditions

  • Wolfram Syndrome

Interventions

  • AMX0035Drug

    AMX0035

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT)Time frame: 24 weeks
  2. To assess the safety and tolerability of AMX0035 administered orally for up to 208 weeks in adult participants with Wolfram syndromeTime frame: 208 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.